Hvis du har foretaget ændringer i Pure, vil de snart blive vist her.

Publikationer 1988 2019

Filtrer
Konferenceabstrakt i tidsskrift
2018

EUROPEAN POST-APPROVAL SAFETY STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SAFETY IN PATIENTS TREATED WITH POMALIDOMIDE IN A REAL-WORLD SETTING

Schmidt-Hieber, M., Abildgaard, N., Gamberi, B., Di Raimondo, F., Ramirez Payer, A., Kyriakou, C., Froen, H. F., Izarra, A. I., Kueenburg, E. ., Di Micco, A., Rosettani, B., Bacon, P., Atiba-Davies, M. & Plesner, T., 15. jun. 2018, I : EHA Learning Center.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Abildgaard, N., Vekemans, M-C., Gamberi, B., Di Raimondo, F., Ramirez Payer, A., Kyriakou, C., Kentos, A., Kueenburg, E. ., Di Micco, A., Rosettani, B., Bacon, P., Atiba-Davies, M. & Plesner, T., 2. dec. 2018, I : Blood. 132, Suppl.1, s. 3286 1 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2017

FDG PET/CT in multiple myeloma: changed FDG uptake in the brain of patients receiving high dose chemotherapy

Østergaard, B., Shamchi, S. P., Taghvaei, R., Zirakchian, M. Z., Raynor, W., Nielsen, A. L., Holdgaard, P. C., Plesner, T., Abildgaard, N., Alavi, A. & Høilund-Carlsen, P. F., 2017, I : European Journal of Nuclear Medicine and Molecular Imaging. 44, 2 Suppl., s. 483-484 EP-0127.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

FDG-PET/CT in multiple myeloma: dual time point imaging results can predict response to treatment in patients recieving high dose chemotherapy

Østergaard, B., Taghvaei, R., Nielsen, A. L., Zirakchian, M. Z., Raynor, W., Asmussen, J. T., Holdgaard, P. C., Plesner, T., Abildgaard, N., Alavi, A. & Høilund-Carlsen, P. F., 2017, I : European Journal of Nuclear Medicine and Molecular Imaging. 44, 2 Suppl., s. 483 1 s., WHO 2016 C.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Stege, C. A. M., van der Holt, B., Mellqvist, U-H., Levin, M-D., Salomo, M., Abildgaard, N., Bos, G., Visser-Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Gruber, A., Coenen, J. L. L. M., Plesner, T., Klein, S., Tanis, B., Szatkowski, D. L., Brouwer, R., Westerman, M., Leijs, M. B. & 11 flere, Sinnige, H., Haukås, E., van der Hem, K., Durian, M. F., Mattijssen, V., Gimsing, P., Van De Donk, N. WCJ., Stevens-Kroef, M., Sonneveld, P., Waage, A. & Zweegman, S., 2017, I : Blood. 130, Suppl. 1, 3146.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

NaF-PET/CT in multiple myeloma: assessing bone remodeling at baseline in newly diagnosed myeloma patients compared to a healthy control group

Østergaard, B., Zadeh, M., Raynor, W., Taghvaei, R., Nielsen, A. L., Asmussen, J. T., Plesner, T., Abildgaard, N., Alavi, A. & Høilund-Carlsen, P. F., 2017, I : European Journal of Nuclear Medicine and Molecular Imaging. 44, 2 Suppl., s. 484-485 EP-0128.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

NaF-PET/CT in multiple myeloma: assessing bone remodeling at baseline in newly diagnosed myeloma patients compared to a healthy control group

Østergaard, B., Zadeh, M., Raynor, W., Taghvaei, R., Nielsen, A. L., Holdgaard, P. C., Asmussen, J. T., Plesner, T., Abildgaard, N., Alavi, A. & Høilund-Carlsen, P. F., 2017, I : European Journal of Nuclear Medicine and Molecular Imaging. 44, Suppl. 2, s. 484 1 s., EP-0128.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma: results of the HOVON87/NMSG18 study

Stege, C. A. M., Kongsgaard Nielsen, L., Witte, B., van der Holt, B., Mellqvist, U-H., Salomo, M., Bos, G., Levin, M-D., Visser-Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Gruber, A., Coenen, J., Plesner, T., Klein, S., Tanis, B., Szatkowski, D. L., Brouwer, R., Westerman, M. & 14 flere, Leys, R., Sinnige, H., Haukås, E., van der Hem, K., Durian, M., Mattijssen, V., Mattijssen, V., Gimsing, P., van de Donk, N., Stevens-Kroef, M., Sonneveld, P., Waage, A., Zweegman, S. & Abildgaard, N., 2017, I : Haematologica. 102, S2, s. 190 1 s., S501.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2016

18F-FDG-PET/CT in Multiple Myeloma: High Intense PET Positive Lesions at Diagnosis Harbor Cytogenetic Adverse Subclones

Østergaard, B., Nielsen, A. L., Møller, H. E. H., Preiss, B. S., Asmussen, J. T., Mortensen, J. R., Plesner, T., Gerke, O., Alavi, A., Høilund-Carlsen, P. F. & Abildgaard, N., 2016, I : Blood. 128, 22, 3260.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

FDG-PET/CT in multiple myeloma: Correlation between SUV and standard prognostic scoring system in multiple myeloma

Østergaard, B., Nielsen, A. L., Gerke, O., Mortensen, J. R., Asmussen, J. T., Plesner, T., Ormstrup, T., Holdgaard, P. C., Abildgaard, N., Alavi, A. & Høilund-Carlsen, P. F., 2016, I : European Journal of Nuclear Medicine and Molecular Imaging. 43, 1 Suppl. 1, s. S438 1 s., EP559.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders: a Study of the International Myeloma Working Group

Hillengass, J., Monopoulos, L. A., Delorme, S., Koutoulidis, V., Hielscher, T., Engelhart, J., Drake, M. T., Rajkumar, V., Østergaard, B., Abildgaard, N., Hinge, M., Plesner, T., Suehara, Y., Matsue, K., Caers, J., Withofs, N., Dimopoulos1, M., Goldschmidt, H., Lentzsch, S., Durie, B. G. & 1 flere, Terpos, E., 2016, I : Blood. 128, 22, 4468.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2015

Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody

McCudden, C., Axel, A., Slaets, D., Frans, S., Bald, J., Schecter, J. M., Ahmadi, T., Plesner, T. & Sasser, K., 2015, I : Journal of Clinical Oncology. 33, 15 Supplement, 8590.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry

Abildgaard, N., Vangsted, A., Gregersen, H., Pedersen, R. S., Plesner, T., Pedersen, P. T., Frederiksen, M., Frølund, U., Helleberg, C., Klausen, T. W. & Gimsing, P., 23. sep. 2015, I : Clinical Lymphoma Myeloma and Leukemia. 2015, Supplement 3, s. e189 1 s., PO-186.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

CT is superior to X-ray in diagnosing osteolytic lesions in the spine and pelvis: a prospective study of newly diagnosed multiple myeloma patients

Hinge, M., Andersen, K. T., Lund, T., Boel-Jørgensen, H., Holdgaard, P., Ormstrup, T., Østergård, L. L. & Plesner, T., 2015, I : Haematologica. 100, S1, s. 501 1 s., E1249.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: Updated results of a phase 1/2 study (GEN503)

Plesner, T., Arkenau, H. T., Gimsing, P., Krejcik, J., Lemech, C., M, C. M., Lassen, U., Laubach, J. P., Palumbo, A., Lisby, S., Basse, L., Wang, J., Sasser, A. K., Guckert, M. E., Yeh, H., Ahmadi, T., Lokhorst, H. M. & Richardson, P. G., 2015, I : Blood. 126, 23, 507.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Efficacy of melflufen, a peptidase targeted therapy, and dexamethasone in an ongoing open-label phase 2a study in patients with relapsed and relapsed-refractory multiple myeloma (RRMM) including an initial report on progression free survival

Voorhees, P. M., Magarotto, V., Sonneveld, P., Plesner, T., Mellqvist, U. H., Paba-Prada, C. E., Byrne, C., Harmenberg, J., Nordstrom, E., Palumbo, A. & Richardson, P., 2015, I : Blood. 126, 23, 3029.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Encouraging Preliminary Data in Ongoing Open-Label Phase 1/2 Study of Safety and Efficacy of Melflufen and *Dexamethasone for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma

Magarotto, V., Sonneveld, P., Voorhees, P., Paba-Prada, C., Plesner, T., Mellqvist, U. H., Byrne, C., Harmenberg, J., Nordstrom, E., Palumbo, A. & Richardson, P., 2015, I : Haematologica. 100, S1, s. 89 1 s., P285.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma

Krejcik, J., Casneuf, T., Nijhof, I., Verbist, B., Bald, J., Plesner, T., Liu, K., Van De Donk, N. W. C. J., Weiss, B., Ahmadi, T., Lokhorst, H. M., Mutis, T. & Sasser, A. K., 2015, I : Blood. 126, 23, 3037.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study

Sezer, O., Terpos, E., Hajek, R., Sucak, G., Cagirgan, S., Linkesch, W., Akay, O. M., Armbrecht, G., Plesner, T., Snowden, J. A., Nahi, H., Gulbas, Z., Potamianou, A., Couturier, C., Olie, R., Feys, C., Allietta, N. & Beksac, M., 2015, I : Clinical Lymphoma Myeloma and Leukemia. 15, S3, s. e129-e130

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Åben adgang

Road-maptoa prospective assessment of frailty in newly diagnosed myeloma patients

Plesner, T., Broch, B., Corradini, A., Andersen, K. & Axelsen, L., 2015, I : Supportive Care in Cancer. 23, S1, s. S98 1 s., 08-09-P.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Åben adgang

Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages

Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Boel-Jørgensen, H., Pallisgaard, N., Kerndrup, G. B. & Plesner, T., sep. 2015, I : Clinical Lymphoma, Myeloma & Leukemia. 15, Supplement 3, s. e144 1 s., PO-112.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2014

Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

Lokhorst, H., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U. N., Krejcik, J., Ahmadi, T., Lisby, S., Basse, L., C. Brun, N. & Richardson, P., 20. maj 2014, I : Journal of Clinical Oncology. 32, 15 (Suppl.), 8513.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

Lokhorst, H. M., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U. N., Krejcik, J., Ahmadi, T., Lisby, S., Basse, L., C. Brun, N. & Richardson, P. G., 2014, I : Journal of Clinical Oncology. 32, 15. Suppl., s. 8513-8513 1 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

Plesner, T., Arkenau, H-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Ahmadi, T., Yeh, H., Guckert, M., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P. G., 2014, I : Journal of Clinical Oncology. 32, 15, 8533.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftFormidling

2012

Daratumumab, a CD38 Monoclonal Antibody in Patients with Mulitple Myeloma - Data From a Dose-Escalation Phase I/II Study

Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Lisby, S. & Richardson, PG., 2012, I : Blood. 120, s. 73

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Daratumumab - a CD38 mAb - for the Treatment of relapsed/Refractory Multiple Myeloma Patients: Preliminary Efficacy Data from Multicenter Phase I/II Study

Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P., 2012, I : Journal of Clinical Oncology. 30, Suppl., s. Abstr.8019

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

2011

Inclusion of myeloma nuclei in osteoclasts activates their resorptive activity

Kupisiewicz, K., Levin Andersen, T., Lund, T., Plesner, T., Kerndrup, G. B., Abildgaard, N., Preiss, B. S. & Delaissé, J-M., 2011, I : Bone. 47, suppl 2, s. 295

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2010

Comparison of zoledronic acid retention in bone of multiple myeloma and breast cancer patients: consequences for efficacy?

Søe, K., Plesner, T., Jakobsen, E. & Jørgensen, HB., 2010, I : Journal of Clinical Oncology. 28, suppl, s. TPS137

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Integrated evaluation of both bone resorption and bone formation highly improves the predictive value of bone markers in patients with myeloma induced bone disease

Lund, T., Hamid, R., Haaber, J. B. B., Levin Andersen, T., Abildgaard, N., Delaissé, J-M. & Plesner, T., 2010, I : Bone. 47, Supplement 2, s. s305 1 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

The proteasome inhibitor bortezomib overcomes the inhibition of osteoblast function observed in multiple myeloma

Lund, T., Søe, K., Abildgaard, N., Garnero, P., Pedersen, PT., Ormstrup, T., Delaissé, J-M. & Plesner, T., 2010, I : Bone. 47, suppl. 2, s. s304 1 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2008

A physical mechanism for coupling bone resorption and formation in adult human bone

Levin Andersen, T., Søndergaard, T. E., Skorzynska, K., Plesner, TL., Plesner, T., Hauge, E. & Delaissé, J-M., 2008, I : Bone. 42, Supl. 1, s. 42

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Biological prerequisistes for heterotypic fusion between myeloma cells and osteoclasts

Kupisiewicz, K., Søe, K., Levin Andersen, T., Søndergaard, T. E., Plesner, T. & Delaissé, J-M., 2008, I : Cancer Treatment Reviews. 34

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by Bortezomib

Lund, T., Søe, K., Abildgaard, N., Garnero, P., Pedersen, PT., Delaissé, J-M. & Plesner, T., 2008, I : Blood. s. 5183

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Myeloma cell-induced collapse of the vascular bone remodeling compartments leads to osteolysis and the generation of osteoclast-myeloma hybrid cells

Levin Andersen, T., Søe, K., Søndergaard, T. E., Kupisiewicz, K., Plesner, T. & Delaissé, J-M., 2008, I : Calcified Tissue International. 82, 1, s. 48

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Osteolysis and the generation of osteoclast-myeloma hybrid cells are related to the myeloma cell-induced collapse of the Vascular Bone Remodeling Compartments

Levin Andersen, T., Søe, K., Søndergaard, T. E., Kupisiewicz, K., Plesner, T. & Delaissé, J-M., 2008, I : Cancer Treatment Reviews. 34, Suppl. 1, s. S55 1 s., OC14.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Proteasome inhibition enhances anti-myeloma and anti-osteoclastic effects of glucocorticoids and weakens the anti-osteoblastic effects

Søe, K., Levin Andersen, T., Plesner, T. & Delaissé, J-M., 2008, I : Cancer Treatment Reviews. 34, Suppl. 1, s. 13-13 1 s., P2.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Proteasome inhibition protects osteoblasts from glucocorticoid-induced damage, and enhances glucocorticoid-induced toxicity against osteoclasts

Søe, K., Levin Andersen, T., Plesner, T. & Delaissé, J-M., 2008, I : Bone. 42, Supplement 1, s. S30-S31

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

The bone degradation marker CTX is a unique marker for disease progression in multiple myeloma

Lund, T., Delaissé, J-M., Abildgaard, N., Kupisiewicz, K. & Plesner, T., 2008, I : Cancer Treatment Reviews. 34, s. 33-33

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

The bone degradation marker CTX shows unique properties in disease monitoring compared to NTX, ICTP and bALP in multiple myeloma

Lund, T., Delaissé, J-M., Abildgaard, N., Kupisiewicz, K., Levin Andersen, T., Søe, K. & Plesner, T., 2008, I : Journal of Bone and Mineral Research. 23, s444

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2007

Bortezomib protects osteoblasts from glucocorticoid-induced damage, and enhances glucocorticoidinduced toxicity against osteoclasts and myeloma cells

Søe, K., Levin Andersen, T., Kupisiewicz, K., Plesner, T. & Delaissé, J-M., 2007, I : Blood. 110, s. 1031A 1032 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Collapse of the vascular bone remodeling compartment is a key process in the development of myelomainduced osteolysis

Andersen, TL., Søndergaard, TE., Søe, K., Plesner, T. & Delaissé, J-M., 2007, I : Journal of Bone and Mineral Research. 22, s. 3 3 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

High dose Simvastatin has no beneficial effect on markers of bone turn-over in multiple myeloma

Søndergaard, TE., Pedersen, PT., Andersen, TL., Lund, T., Garnero, P., Delaissé, J-M. & Plesner, T., 2007, I : Blood. 4824, s. 280B 280 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Identification of a highly specialized micro-anatomical structure that is a key player in myeloma bone disease

Levin Andersen, T., Søndergaard, TE., Boissy, P., Skorzynska, EK., Plesner, T., Hauge, E. & Delaissé, J-M., 2007, I : Haematologica. 92, Suppl. 2, s. 127 127 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Intermittent treatment with bortezomib inhibits transiently osteoclasts resorptive activity

Boissy, P., Lund, T., Levin Andersen, T., Plesner, T. & Delaissé, J-M., 2007, I : Haematologica. 92, suppl. 2, s. 132 132 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Resveratrol analogs as petential treatment of multiple myeloma and bone related disease: Effect on myeloma cells, osteoclasts and osteoblasts in vitro

Kupisiewicz, K., Boissy, P., Søe, K., Abdallah, B., Kassem, M., Plesner, T. & Delaissé, J-M., 2007, I : Calcified Tissue International. 80, s. 65

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

Resveratrol and its analogs for treating multiple myeloma

Kupisiewicz, K., Boissy, P., Søe, K., Abdallah, B., Kassem, M., Plesner, T. & Delaissé, J-M., 2007, I : Haematologica. 92, s. 131 132 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning